Hemogenyx Pharmaceuticals Plc
HOPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3,271 | $36 | $11 | $17 |
| - Cash | $159 | $1,248 | $2,533 | $6,841 |
| + Debt | $2,623 | $2,946 | $3,423 | $10 |
| Enterprise Value | $5,735 | $1,734 | $901 | -$6,814 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$800 | $0 | -$2,600 | -$284 |
| % Margin | – | – | – | – |
| EBITDA | -$5,147 | -$5 | -$5,441 | -$2,576 |
| % Margin | – | – | – | – |
| Net Income | -$5,619 | -$7 | -$3,979 | -$5,099 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.13 | -2.37 | -1.62 | -2.64 |
| % Growth | 10.1% | -46.3% | 38.6% | – |
| Operating Cash Flow | -$4,140 | -$6,106 | -$2,911 | -$2,627 |
| Capital Expenditures | -$13 | -$117 | -$429 | -$818 |
| Free Cash Flow | -$4,153 | -$6,223 | -$3,340 | -$3,445 |